sulfaphenazole has been researched along with ascorbic acid in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Breuer, S; Busse, R; Dimmeler, S; Fichtlscherer, S; Fleming, I; Zeiher, AM | 1 |
| Cipriano, A; Franzoni, F; Galetta, F; Ghiadoni, L; Magagna, A; Salvetti, A; Taddei, S; Versari, D; Virdis, A | 1 |
| Ambrogini, E; Banti, C; Bernini, G; Carrara, D; Cetani, F; Ghiadoni, L; Giannarelli, C; Marcocci, C; Pinchera, A; Taddei, S; Virdis, A | 1 |
1 trial(s) available for sulfaphenazole and ascorbic acid
| Article | Year |
|---|---|
Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.
Topics: Acetylcholine; Adult; Aryl Hydrocarbon Hydroxylases; Ascorbic Acid; Blood Proteins; Coronary Artery Disease; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Enzyme Inhibitors; Forearm; Humans; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Oxidation-Reduction; Regional Blood Flow; Sulfaphenazole; Vasodilation; Vasodilator Agents | 2004 |
3 other study(ies) available for sulfaphenazole and ascorbic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients.
Topics: Acetylcholine; Adult; Aryl Hydrocarbon Hydroxylases; Ascorbic Acid; Biological Factors; Bradykinin; Case-Control Studies; Cytochrome P-450 CYP2C9; Drug Combinations; Drug Synergism; Endothelium, Vascular; Enzyme Inhibitors; Female; Forearm; Humans; Hypertension; Male; Microcirculation; Middle Aged; Nitroprusside; omega-N-Methylarginine; Regional Blood Flow; Sulfaphenazole; Vasodilation; Vasodilator Agents | 2006 |
The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Ascorbic Acid; Biological Factors; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Female; Humans; Hyperparathyroidism, Primary; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Parathyroidectomy; Sulfaphenazole; Vasodilation | 2010 |